Strongyloides Stercoralis InfectionSCANNCT07009613

Strongyloides Stercoralis Public Health Control in Rwanda

An observational study of Strongyloides Stercoralis Infection and Strongyloides, run by IRCCS Sacro Cuore Don Calabria di Negrar at 1 site in Rwanda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 5 years and older
Conditions the study is for: Strongyloides Stercoralis Infection, Strongyloides
What is being tested?: Parasitological tests and Questionnaire
How many people: 1,415 participants
Where: 1 siteRwanda
Study dates: 23 Sep 2024to 14 Oct 2024
How long will I take part?: 1 Day
Phase: Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 5 years and older
All sexes
No healthy volunteers
Child, Adult, Older adult

Study population: People living in two districts in Rwanda

Who may be able to join

People living in the selected districts and households
Obtainment of written informed consent (for children's participation, consent was sought from parents/guardians).

Who cannot join

Inability to supply an adequate stool sample

Trial locations and contacts

1 site in 1 country.

Rwanda1 site

School of Health Sciences, College of Medicine and Health Sciences, University of Rwanda
Kigali, 737

Other trials in Rwanda

About this study

Official title: Integration of Strongyloides Stercoralis Public Health Control Into the Soil-transmitted Helminths Control Programme in Rwanda - The SCAN Study

The World Health Organization (WHO) recently issued guideline for the public health control of Strongyloides stercoralis in endemic areas. We aimed to evaluate the feasibility of implementing the WHO recommendations in Rwanda, specifically to intergrate the activities for the public health control of strongyloidiasis in the ongoing national programme for the control of the other soil-transmitted helminths and schistosomiasis, that has been in place for several years. As additional objective, we aimed to estimate the prevalence of S. stercoralis in two districts of Rwanda (Gisagara and Rubavu). To evaluate the feasibility, we asked lab technicians to evaluate challenges emerged during the implementation of the laboratory procedures with a structured questionnaire. Also, we evaluated the costs needed to perform these tests. We estimated the prevalence of S. stercoralis by calculating the number of positive cases out of all people tested. The lab technicians participated to a training session, where they were taught the S. stercoralis-specific lab techniques, and to a two-day pilot study where they could practice. The tests used were parasitological techniques (agar stool culture, (APC) and Baermann method) and an antibody rapid diagnostic test (RDT). Duration of training, with a specific focus on larvae differentiation, was identified as pivotal for a successful implementation of the parasitological techniques. The use of the RDT was instead considered easy to apply at all evaluation time points. Raw cost (i.e. not including staff salaries and transport costs) of materials and equipment was below 2 euros/test for each assay. In both districts, Strongyloides prevalence was below the threshold recommended by the WHO for the implementation of mass treatment, hence this aspect was not evaluated.

Conditions: Strongyloides Stercoralis Infection, Strongyloides
Being tested: Parasitological tests, Questionnaire

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Parasitological testsDiagnostic test
The primary outcome was reported based on the technicians' answers collected with a structured questionnaire. The individuals screened underwent testing with the tests detailed above
QuestionnaireOther
The primary outcome was based on the technicians' evaluation, based on their answers collected in a questionnaire. The individuals screened were tested with assays used for the national control programmes

What is being measured

The primary outcome is the main question the study is designed to answer.

Evaluation of the tests based on technicians' perception (through questionnaire) and costs
Technicians' previous experience with each S. stercoralis-specific assay, along with their perceptions regarding the ease of each of the procedural steps and associated safety concerns were assessed using a structured questionnaire. Each procedural step was rated as "Very easy", "Easy", "Neutral", "Difficult" and "Very difficult". For the steps marked "difficult" or "very difficult", respondents could specify the reasons for the difficulty from a predefined non-mutually-exclusive list of options. The per-test costs were calculated from the procurement records of each S. stercoralis-specific assay.
Measured: The data will be collected at baseline, during the pilot study (two - three days from baseline) and during field work (after two to three weeks from baseline)

Secondary outcomes (1)

Prevalence
Frequency of S. stercoralis cases out of the tested population
Measured: through study completion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

23 Sep 202414 Oct 2024

First posted6 Jun 2025
Study start23 Sep 2024
Primary completion11 Oct 2024
Study completion14 Oct 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Strongyloides Stercoralis InfectionStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Cross-sectional
Enrolment: 1,415 participants (actual)
Target duration: 1 Day

IDs, dates and publications

ClinicalTrials.gov ID: NCT07009613
Sponsor's protocol ID: No477/RNEC/2024
Acronym: SCAN
Status last verified: Jun 2025
First submitted: 17 May 2025
Last updated: 6 Jun 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Evaluation of the Rapid Diagnostic Test SsRT+ for Strongyloides Stercoralis
Strongyloides Stercoralis Infection, Device Performance
RecruitingObservational study
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Dengue, Chikungunya

All Strongyloides Stercoralis Infection trials